• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 453231 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416977370 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416977370 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Hot Stock: EnteroMedics, Shares Gain 7.2% (ETRM)

Published on Tue, 03/05/2013 - 13:23
By Adrienne Chilton

EnteroMedics (NASDAQ:ETRM) is one of today's best performing penny stocks, up 7.2% to $0.95 on 1.1x average daily volume. Thus far today, EnteroMedics has traded 1.6 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (7.2% to the Dow's 1.0%) and outperformed the S&P 500 (7.2% to the S&P's 1.0%) during today's trading.

EnteroMedics has overhead space with shares priced $0.95, or 76.9% below the average consensus analyst price target of $4.12. The stock should find initial resistance at its 50-day moving average (MA) of $2.15 and further resistance at its 200-day MA of $3.04.

In the past 52 weeks, EnteroMedics share prices have been bracketed by a low of $0.81 and a high of $4.40 and are now at $0.95, 18% above that low price. The 200-day and 50-day moving averages have moved 0.95% lower and 3.99% lower over the past week, respectively.

EnteroMedics Inc. is a development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Shares of Ventas Rise Above Previous 52-...

Ventas (NYSE:VTR) traded today at a new 52-week high of $70.11. So far today approxima ...

Shares of Validus Holdings Rise to a New...

Shares of Validus Holdings (NYSE:VR) traded at a new 52-week high today of $41.42. So ...

Watch for Continued Gains in Shares of V...

Shares of VF Corp (NYSE:VFC) traded today at $74.38, breaking its 52-week high. This n ...

Shares of Valspar Have Risen Above Previ...

Valspar (NYSE:VAL) traded at a new 52-week high today of $87.59. Approximately 849,000 ...

Visa: The Winning Streak Continues (V)...

Visa (NYSE:V) traded today at a new 52-week high of $258.00. So far today approximatel ...

Union Pacific Looks to Continue to Trade...

Union Pacific (NYSE:UNP) traded today at a new 52-week high of $123.61. This new high ...

Shares of Textron Have Risen Above Previ...

Textron (NYSE:TXT) traded at a new 52-week high today of $44.47. This new high was rea ...

Shares of Take-Two Interactive Software ...

Take-Two Interactive Software (NASDAQ:TTWO) traded today at a new 52-week high of $28.0 ...